Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial

Göran Tornling; Rohit Batta; Joanna C Porter; Bryan Williams; Thomas Bengtsson; Kartikeya Parmar; Reema Kashiva; Anders Hallberg; Anne Katrine Cohrt; Kate Westergaard; Carl-Johan Dalsgaard; Johan Raud

doi:10.1016/j.eclinm.2021.101152

Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial

EClinicalMedicine. 2021 Nov:41:101152. doi: 10.1016/j.eclinm.2021.101152. Epub 2021 Oct 24.

Authors

Affiliations

¹ Respiratory Medicine Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
² Vicore Pharma AB, Gothenburg, Sweden.
³ UCL Respiratory, Univeristy College London and Department of Thoracic Medicine, University College Hospital, London, UK.
⁴ Institute of Cardiovascular Science, University College London and National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, London, UK.
⁵ StatMind AB, Lund, Sweden.
⁶ B J Medical College and Department of Medicine, Civil Hospital, Asarwa, Ahmedabad Gujarat, India.
⁷ Department of Medicine, Noble Hospitals Pvt. Ltd, Hadapsar, Pune, Maharashtra, India.
⁸ Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
⁹ Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Abstract

Background: COVID-19 morbidity and mortality remains high and the need for safe and effective drugs continues despite vaccines.

Methods: Double-blind, placebo-controlled, multi-centre, randomised, parallel group phase 2 trial to evaluate safety and efficacy of oral angiotensin II type 2 receptor agonist C21 in hospitalized patients with COVID-19 and CRP ≥ 50-150 mg/L conducted at eight sites in India (NCT04452435). Patients were randomly assigned 100 mg C21 bid or placebo for 7 days in addition to standard of care. Primary endpoint: reduction in CRP. The study period was 21 July to 13 October 2020.

Findings: 106 patients were randomised and included in the analysis (51 C21, 55 placebo). There was no significant group difference in reduction of CRP, 81% and 78% in the C21 and placebo groups, respectively, with a treatment effect ratio of 0.85 [90% CI 0.57, 1.26]. In a secondary analysis in patients requiring supplemental oxygen at randomisation, CRP was reduced in the C21 group compared to placebo. At the end of the 7-day treatment, 37 (72.5%) and 30 (54.5%) of the patients did not require supplemental oxygen in the C21 and placebo group, respectively (OR 2.20 [90% CI 1.12, 4.41]). A post hoc analysis showed that at day 14, the proportion of patients not requiring supplemental oxygen was 98% and 80% in the C21 group compared to placebo (OR 12.5 [90% CI 2.9, 126]). Fewer patients required mechanical ventilation (one C21 patient; four placebo patients), and C21 was associated with a numerical reduction in the mortality rate (one vs three in the C21 and placebo group, respectively). Treatment with C21 was safe and well tolerated.

Interpretation: Among hospitalised patients with COVID-19 receiving C21 for 7 days there was no reduction in CRP compared to placebo. However, a post-hoc analysis indicated a marked reduction of requirement for oxygen at day 14. The day 14 results from this study justify further evaluation in a Phase 3 study and such a trial is currently underway.

Funding: Vicore Pharma AB and LifeArc, UK.

Keywords: COVID-19; acute hospitalizations; angiotensin II type 2 receptor; pharmacologic treatment; viral pneumonia.